A detailed history of Vanguard Group Inc transactions in Anebulo Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 154,036 shares of ANEB stock, worth $249,538. This represents 0.0% of its overall portfolio holdings.

Number of Shares
154,036
Previous 153,873 0.11%
Holding current value
$249,538
Previous $420,000 29.29%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.77 - $3.08 $288 - $502
163 Added 0.11%
154,036 $297,000
Q2 2024

Aug 13, 2024

BUY
$1.9 - $3.12 $761 - $1,251
401 Added 0.26%
153,873 $420,000
Q1 2024

May 10, 2024

BUY
$2.34 - $3.0 $1,097 - $1,407
469 Added 0.31%
153,472 $440,000
Q4 2023

Feb 14, 2024

BUY
$1.71 - $3.17 $223,426 - $414,189
130,659 Added 584.76%
153,003 $370,000
Q3 2023

Nov 14, 2023

BUY
$2.15 - $3.49 $13,570 - $22,028
6,312 Added 39.37%
22,344 $68,000
Q2 2023

Aug 14, 2023

BUY
$2.06 - $2.98 $33,025 - $47,775
16,032 New
16,032 $37,000

Others Institutions Holding ANEB

About Anebulo Pharmaceuticals, Inc.


  • Ticker ANEB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,633,200
  • Market Cap $41.5M
  • Description
  • Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The ...
More about ANEB
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.